Metabotropic glutamate receptor 2

Addex, Stanford University and University of Copenhagen Publish mGlu2 Structure in Nature Using Addex Allosteric Modulators

Retrieved on: 
Thursday, July 1, 2021
Allosteric modulator, Neuropharmacology, Allosteric regulation, Metabotropic glutamate receptor 2, Branches of biology, Chemistry, Cell biology

The study , published in Nature, was headed by Professor Georgios Skiniotis (Stanford University) in collaboration with the University of Copenhagen and Addex.

Key Points: 
  • The study , published in Nature, was headed by Professor Georgios Skiniotis (Stanford University) in collaboration with the University of Copenhagen and Addex.
  • Access to unique allosteric modulators stemming from Addexs expertise was invaluable as we elucidated these mGlu2 receptor structures, said Skiniotis.
  • The Nature publication explains how the mGlu2 receptor undergoes profound conformational transitions from an inactive to an active state.
  • Addex has developed unique capabilities that have allowed the industrialization of allosteric modulator discovery, including extensive expertise in targeting the mGlu2 receptor.

Addex ADX71149 Receives IND Approval to Start a Phase 2a Clinical Study in Epilepsy

Retrieved on: 
Thursday, January 21, 2021
Drugs, Chemical compounds, Pyridines, Organic compounds, ADX-71149, Chloroarenes, Lactams, Metabotropic glutamate receptor 2, Levetiracetam, Allosteric modulator

IND approval for the mGlu2 epilepsy study is great news to start 2021 and will be the first of three clinical studies we expect to be initiate this year, said Tim Dyer, CEO of Addex.

Key Points: 
  • IND approval for the mGlu2 epilepsy study is great news to start 2021 and will be the first of three clinical studies we expect to be initiate this year, said Tim Dyer, CEO of Addex.
  • Wed like to thank the team involved for their continued support and moving quickly to get this clinical study ready for patient enrolment.
  • The primary objective of the study is to evaluate the efficacy of JNJ-40411813 (ADX71149) in combination with levetiracetam using a time-to-event endpoint.
  • Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc, is scheduled to enter a phase 2a proof of concept clinical study for the treatment of epilepsy in Q2 2021.

Addex mGlu2 PAM Program to Advance into Epilepsy Phase 2a Proof of Concept Clinical Study

Retrieved on: 
Tuesday, June 16, 2020
Organic compounds, Chemical compounds, Pyridines, ADX-71149, Chloroarenes, Lactams, Neuroscience, Metabotropic glutamate receptor 2, Janssen Pharmaceutica, Cognitive disorder, Neurocognitive, PAM

The decision of Janssen to advance ADX71149 into a Phase 2 clinical study is an exciting development and an important achievement for us, said Tim Dyer, CEO of Addex.

Key Points: 
  • The decision of Janssen to advance ADX71149 into a Phase 2 clinical study is an exciting development and an important achievement for us, said Tim Dyer, CEO of Addex.
  • Under the research collaboration and license agreement, Addex granted Janssen an exclusive worldwide license to develop and commercialize mGlu2 PAM compounds.
  • Addex's second clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for the treatment of epilepsy.
  • Preclinical programs include GABABPAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinsons disease and mGlu3 PAM for neurodegenerative disorders.

Addex Therapeutics to Report 2019 Full Year Audited Results on April 8, 2020

Retrieved on: 
Monday, April 6, 2020
Metabotropic glutamate receptors, Branches of biology, Cell biology, Metabotropic glutamate receptor 2, Allosteric regulation, Metabotropic glutamate receptor 3, Allosteric modulator, Metabotropic glutamate receptor 4, Small molecule, Cognitive disorder

1: In the 10 minutes prior to the call start time, call the appropriateparticipant dial-in number.

Key Points: 
  • 1: In the 10 minutes prior to the call start time, call the appropriateparticipant dial-in number.
  • Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.
  • Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
  • Preclinical programs include GABABPAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinsons disease and mGlu3 PAM for neurodegenerative disorders.

Addex Therapeutics to Report 2019 Full Year Audited Results on March 19, 2020

Retrieved on: 
Friday, March 13, 2020
Metabotropic glutamate receptors, Branches of biology, Cell biology, Metabotropic glutamate receptor 2, Allosteric regulation, Metabotropic glutamate receptor 3, Allosteric modulator, Metabotropic glutamate receptor 4, Small molecule, Cognitive disorder

1: In the 10 minutes prior to the call start time, call the appropriateparticipant dial-in number.

Key Points: 
  • 1: In the 10 minutes prior to the call start time, call the appropriateparticipant dial-in number.
  • Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.
  • Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
  • Preclinical programs include GABABPAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinsons disease and mGlu3 PAM for neurodegenerative disorders.